Research programme: DNA interacting protein degrader therapeutics - Valerio Therapeutics
Alternative Names: DecoyTACLatest Information Update: 29 Dec 2023
At a glance
- Originator Valerio Therapeutics
- Class Antineoplastics; DNA
- Mechanism of Action Proteolysis; Transcription factor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 19 Dec 2023 Early research in Cancer in France (Parenteral) (Valerio Therapeutics pipeline, December 2023)
- 19 Dec 2023 Valerio Therapeutics plans IND-enabling studies for Cancer in France (Parenteral) in second half of 2024 (Valerio Therapeutics pipeline, December 2023)